Studies on the role of HMT inhibitors in resistance have entered clinical trial phases, with the EZH2 inhibitor EPZ-6438 (Tazemetostat) undergoing trials in platinum-resistant small cell lung cancer patients (Trial ID: NCT05353439). The gene discussed is EZH2; the disease is small cell lung carcinoma.